Page de couverture de S1E6 - SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action

S1E6 - SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action

S1E6 - SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

 Visit http://morningcommutepodcast.com/SGLT2inhibitors6 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. James Januzzi and Dr. Silvio Inzucchi discuss the surge in collaboration between primary care physicians, endocrinologists, and cardiologists and the groundswell of cardiometabolic clinics. They attribute this to cardiologists moving beyond the so-called glucocentric view and focusing on how diabetes therapies might help reduce cardiovascular risk as well. Drs. Januzzi and Inzucchi will also discuss the recent guidelines that now incorporate sodium-glucose cotransporter 2 (SGLT-2) inhibitors into clinical pathways.

Ce que les auditeurs disent de S1E6 - SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.